{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:23:01Z","timestamp":1772220181657,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:00:00Z","timestamp":1408752000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Peptide receptor radionuclide therapy (PRRT) is routinely used for advanced or metastasized neuroendocrine tumours (NET). To prevent nephrotoxicity, positively charged amino acids (AA) are co-infused. The aim of this study was to correlate the risk for therapy-related hyperkalaemia with the total amount of AA infused.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-two patients undergoing PRRT with standard activities of <jats:sup>177<\/jats:sup>Lu-DOTATATE\/-TOC were monitored during two following treatment cycles with co-infusion of 75 and 50\u00a0g of AA (<jats:sc>l<\/jats:sc>-arginine and <jats:sc>l<\/jats:sc>-lysine), respectively. Mean serum levels of potassium and other parameters (glomerular filtration rate [GFR], creatinine, blood urea nitrogen [BUN], phosphate, chloride, lactate dehydrogenase) prior to, 4\u00a0h and 24\u00a0h after AA infusion were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Self-limiting hyperkalaemia (&gt;5.0\u00a0mmol\/l) resolving after 24\u00a0h occurred in 91% (20\/22) of patients in both protocols. Potassium levels, BUN, creatinine, GFR, phosphate, chloride and LDH showed a similar range at 4\u00a0h after co-infusion of 75 or 50\u00a0g of AA, respectively (<jats:italic>p<\/jats:italic>?&gt;?0.05). Only GFR and creatinine levels at 24\u00a0h varied significantly between the two co-infusion protocols (<jats:italic>p<\/jats:italic>?&lt;?0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hyperkalaemia is a frequent side effect of AA infusion in PRRT. Varying the dose of co-infused amino acids did not impact on the incidence and severity of hyperkalaemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13550-014-0046-2","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T13:55:58Z","timestamp":1408715758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy"],"prefix":"10.1186","volume":"4","author":[{"given":"Constantin","family":"Lapa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Bluemel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"L\u00fcckerath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Strate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas K","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"key":"46_CR1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jnci\/djn275","volume":"100","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008, 100: 1282\u20131289. 10.1093\/jnci\/djn275","journal-title":"J Natl Cancer Inst"},{"key":"46_CR2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2967\/jnumed.108.061457","volume":"50","author":"B Waser","year":"2009","unstructured":"Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC: Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009, 50: 936\u2013941. 10.2967\/jnumed.108.061457","journal-title":"J Nucl Med"},{"key":"46_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.bpg.2013.01.004","volume":"26","author":"H Bergsma","year":"2012","unstructured":"Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ: Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012, 26: 867\u2013881. 10.1016\/j.bpg.2013.01.004","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"46_CR4","doi-asserted-by":"crossref","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke HR, Rochlitz C, Muller-Brand J, Walter MA: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011, 29: 2416\u00bf2423.","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"46_CR5","doi-asserted-by":"crossref","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26: 2124\u00bf2130.","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"46_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","volume":"31","author":"L Bodei","year":"2004","unstructured":"Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G: Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31: 1038\u20131046. 10.1007\/s00259-004-1571-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"46_CR7","unstructured":"Forrer F, Waldherr C, Maecke HR, Mueller-Brand J: Targeted radionuclide therapy with90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006, 26: 703\u00bf707."},{"key":"46_CR8","unstructured":"Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP: Long-term follow-up of renal function after peptide receptor radiation therapy with(90)Y-DOTA(0), Tyr(3)-octreotide and(177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005, 46(Suppl 1):83S\u00bf91S."},{"key":"46_CR9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013, 40: 800\u2013816. 10.1007\/s00259-012-2330-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"46_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002590050216","volume":"25","author":"TM Behr","year":"1998","unstructured":"Behr TM, Goldenberg DM, Becker W: Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998, 25: 201\u2013212. 10.1007\/s002590050216","journal-title":"Eur J Nucl Med"},{"key":"46_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/ndt\/gfh362","volume":"19","author":"R Barone","year":"2004","unstructured":"Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, Bouterfa H, Devuyst O, Jamar F: Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 2004, 19: 2275\u20132281. 10.1093\/ndt\/gfh362","journal-title":"Nephrol Dial Transplant"},{"key":"46_CR12","first-page":"617","volume":"43","author":"M de Jong","year":"2002","unstructured":"de Jong M, Krenning E: New advances in peptide receptor radionuclide therapy. J Nucl Med 2002, 43: 617\u2013620.","journal-title":"J Nucl Med"},{"key":"46_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP: Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003, 30: 9\u201315. 10.1007\/s00259-002-0982-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"46_CR14","first-page":"1929","volume":"38","author":"BF Bernard","year":"1997","unstructured":"Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Macke H, de Jong M: D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997, 38: 1929\u20131933.","journal-title":"J Nucl Med"},{"key":"46_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP: [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med 2001, 28: 1319\u20131325. 10.1007\/s002590100574","journal-title":"Eur J Nucl Med"},{"key":"46_CR16","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00259-011-1826-9","volume":"38","author":"G Giovacchini","year":"2011","unstructured":"Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F: Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging 2011, 38: 1675\u20131682. 10.1007\/s00259-011-1826-9","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-014-0046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-014-0046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-014-0046-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-014-0046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:18:08Z","timestamp":1630559888000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-014-0046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,23]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1186\/s13550-014-0046-2","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,23]]},"assertion":[{"value":"7 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"46"}}